Posted May 27, 2020
On May 18, 2020, Moderna, Inc. of Cambridge, Massachusetts announced that it had obtained “positive interim clinical data” from a Phase I human clinical trial of its experimental mRNA-1273 COVID-19 vaccine that began on Mar. 16. The biotechnology company said that eight of the 45 healthy adult volunteer trial subjects developed antibodies that may provide protection from the SARS-CoV-2 virus that causes COVID-19.1 2 3 The company also reported that four participants suffered Grade 3 vaccine reactions. Read more.